Shares of Wockhardt are likely to remain in focus after the pharmaceutical company reiterated plans to launch its breakthrough antibiotic Zaynich in the United States by the end of 2026 or early 2027, a development that management believes could become one of the company's biggest long-term growth drivers.
The Mumbai-based pharmaceutical and biotechnology company continues to maintain its estimate of a $1 billion peak global market opportunity for Zaynich. According to Founder and Chairman Habil F. Khorakiwala, the United States is expected to contribute around 40-45% of that opportunity, making it the key market for the drug.
Management clarified that the estimate reflects peak sales potential rather than near-term revenue expectations, as adoption of a new hospital antibiotic typically takes time before gaining wider physician acceptance.
Zaynich is designed primarily for treating severe and highly resistant bacterial infections, particularly in intensive care unit (ICU) settings. The company believes the drug's broad-spectrum coverage and ability to deliver rapid clinical outcomes differentiate it from existing treatment options available in the market.
Wockhardt also highlighted that the drug enjoys patent protection until 2038, providing more than a decade of exclusivity following commercialisation.
Beyond its initial approval for complicated urinary tract infections in the US, the company is conducting additional clinical trials to expand the drug's use into pneumonia and other lung infections. These studies are expected to be completed over the next two years and could significantly expand the addressable market opportunity for the product.
Management stated that it currently does not see any antibiotic in development that directly challenges Zaynich's positioning in the treatment of multi-drug resistant infections.
As of June 2, Wockhardt's market capitalisation stood at approximately Rs 34,964 crore. The stock was trading at Rs 340.70 in early trade and has declined more than 2% over the past year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.